Mehrdad Arjomandi, MD

HS CLIN PROF-HCOMP

Dr. Arjomandi grew up in Ahvaz, a small city in Southwestern Iran, and moved to the United States in 1986 in the aftermath of Iranian revolution (1979), Iraq's invasion of Iran (1980-88), and his family displacement inside Iran (1980-83). When in California, he began his higher education at Los Angeles Pierce College before transferring to University of California San Diego in 1988, where he obtained a bachelor degree in molecular biology and completed a senior honors thesis in developmental biology in Dr. Richard Firtel’s lab. He then attended Stanford University School of Medicine in 1991, completing two predoctoral research fellowships in Dr. Etienne Emile Beaulieu’s lab at INSERM in Paris, France, and Dr. John Cooke’s vascular biology lab at Stanford. Dr. Arjomandi then completed a residency in internal medicine at UCLA (1996-99) and a fellowship in pulmonary and critical care at UCSF (2000-03). He completed three additional years of research fellowship funded by the American Lung Association and Chest Foundation before successfully competing for an NIH K23 award in 2006 and then joining the pulmonary and critical care faculty at UCSF and San Francisco General Hospital (SFGH). In 2008, he obtained a joint appointment at San Francisco VA Medical Center (SF VA).

Currently, Dr. Arjomandi is Professor of Medicine in the Divisions of Pulmonary, Critical Care, Allergy, and Sleep Medicine and Occupational and Environmental Medicine at UCSF with a joint appointment at SF VA. He is Director of the UCSF Human Exposure Laboratory at SFGH, Director of Environmental Medicine Clinic at SF VA, Site Director for the SF VA Airborne Hazard Exposure Study Center of Excellence, an investigator at the UCSF Center for Tobacco Control Research and Education, and a member of the UCSF Helen Diller Family Comprehensive Cancer Center.

Research Interests

The lung is constantly exposed to various environmental pollutants, allergens, and toxins, which interact with airways and alveoli and result in inflammation, injury, and disease. My laboratory primary research interest has been centered on the paradigm that respiratory exposures to pollutants and toxicants contribute to development and progression of chronic lung diseases, and may further yield systemic effects well beyond lungs. Under this paradigm, my research activities have focused on understanding the physiologic and immunologic mechanisms via which environmental exposures contribute to chronic lung diseases and how knowledge of these mechanisms could be translated to ways to better define, prognosticate, and manage disease burden at both individual and societal levels.

I have dedicated my efforts to (1) investigate the biology of airway immune cells using inhalational exposure to ozone in humans as a model of lung injury simulating exacerbation in chronic lung disease, and (2) characterize the early cardiopulmonary changes due to exposure to tobacco smoke and the pathophysiology and biology associated with those changes.

Education
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
Certificate, 10/2010 - Genetic Approaches to Complex Heart, Lung and Blood Diseases, The Jackson Laboratories (NIH/NHLBI)
Certificate, 05/2010 - Mentor Development Program, University of California, San Francisco
Certificate, 08/2009 - Clinical Trial Design Course, Veterans Affairs Cooperative Study Program
Certificate, 06/2003 - Advanced Training in Clinical Research, University of California, San Francisco
Fellowship, 06/2003 - Pulmonary & Critical Care Medicine, University of California, San Francisco
Residency, 06/1999 - Internal Medicine, University of California, Los Angeles
MD, 06/1996 - MD Program, Stanford University
BA, 06/1991 - Molecular Biology, University of California, San Diego
Honors and Awards
  • SFVA Dept of Medicine HeRO Award, San Francisco VA Healthcare System, 2022
Websites
Publications
  1. Abrham Y, Zeng S, Lin W, Lo C, Beckert A, Evans L, Dunn M, Giang B, Thakkar K, Roman J, Blanc PD, Arjomandi M. Self-report underestimates the frequency of the acute respiratory exacerbations of COPD but is associated with BAL neutrophilia and lymphocytosis: an observational study. BMC pulmonary medicine 2024. PMID: 39223571


  2. Simoneau CR, Chen PY, Xing GK, Hayashi JM, Chen IP, Khalid MM, Meyers NL, Taha TY, Leon KE, Suryawanshi RK, McCavitt-Malvido M, Ashuach T, Fontaine KA, Rodriguez L, Joehnk B, Walcott K, Vasudevan S, Fang X, Maishan M, Schultz S, Roose JP, Matthay MA, Sil A, Arjomandi M, Yosef N, Ott M. NF-κB inhibitor alpha controls SARS-CoV-2 infection in ACE2-overexpressing human airway organoids. Scientific Reports 2024. PMID: 38961189


  3. Gerard SE, Dougherty TM, Nagpal P, Jin D, Han MK, Newell JD, Saha PK, Comellas AP, Cooper CB, Couper D, Fortis S, Guo J, Hansel NN, Kanner RE, Kazeroni EA, Martinez FJ, Motahari A, Paine Iii R, Rennard S, Schroeder JD, Woodruff PG, Barr RG, Smith BM, Hoffman EA. Vessel and Airway Characteristics in One-Year CT-defined Rapid Emphysema Progression: SPIROMICS. Annals of the American Thoracic Society 2024. PMID: 38530051


  4. Danielle Glick, John Konikkara, Anays Sotolongo, Thomas Alexander, Montserrat Diaz-Abad, Jennifer So, Mehrdad Arjomandi, Silpa Krefft, John Osterholzer, Bradley Richmond, Michael Falvo. 0891 Sleep Quality Among Post-9/11 Veterans with Exposure to Airborne Hazards. Sleep 2024. PMID:


  5. Suri R, Markovic D, Woo H, Arjomandi M, Barr RG, Bowler RP, Criner G, Curtis JL, Dransfield MT, Drummond MB, Fortis S, Han MK, Hoffman EA, Kaner RJ, Kaufman JD, Krishnan JA, Martinez FJ, Ohar J, Ortega VE, Paine Iii R, Soler X, Woodruff PG, Hansel NN, Cooper CB, Tashkin DP, Buhr RG, Barjaktarevic IZ. The Effect of Chronic Altitude Exposure on COPD Outcomes in the SPIROMICS Cohort. American journal of respiratory and critical care medicine 2024. PMID: 38507607


  6. Seedahmed MI, Albirair MT, Whooley MA, Koth LL, Blanc PD, Arjomandi M. Response. Chest 2024. PMID: 38199743


  7. McKleroy W, Shing T, Anderson WH, Arjomandi M, Awan HA, Barjaktarevic I, Barr RG, Bleecker ER, Boscardin J, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Curtis JL, Dransfield M, Doerschuk CM, Dolezal BA, Drummond MB, Han MK, Hansel NN, Helton K, Hoffman EA, Kaner RJ, Kanner RE, Krishnan JA, Lazarus SC, Martinez FJ, Ohar J, Ortega VE, Paine R, Peters SP, Reinhardt JM, Rennard S, Smith BM, Tashkin DP, Couper D, Cooper CB, Woodruff PG. Longitudinal Follow-Up of Participants With Tobacco Exposure and Preserved Spirometry. JAMA 2023. PMID: 37526720


  8. Arjomandi M, Zeng S, Chen J, Bhatt SP, Abtin F, Barjaktarevic I, Barr RG, Bleecker ER, Buhr RG, Criner GJ, Comellas AP, Couper DJ, Curtis JL, Dransfield MT, Fortis S, Han MK, Hansel NN, Hoffman EA, Hokanson JE, Kaner RJ, Kanner RE, Krishnan JA, Labaki W, Lynch DA, Ortega VE, Peters SP, Woodruff PG, Cooper CB, Bowler RP, Paine R, Rennard SI, Tashkin DP, and the COPDGene and SPIROMICS Investigators. Changes in Lung Volumes with Spirometric Disease Progression in COPD. Chronic obstructive pulmonary diseases (Miami, Fla.) 2023. PMID: 37199719


  9. Seedahmed MI, Albirair MT, Whooley MA, Koth LL, Blanc PD, Arjomandi M. Screening for Exposure to Beryllium Among US Veterans With a Diagnosis of Sarcoidosis, 2002-2020. Chest 2023. PMID: 37364853


  10. Seedahmed MI, Baugh AD, Albirair MT, Luo Y, Chen J, McCulloch CE, Whooley MA, Koth LL, Arjomandi M. Epidemiology of Sarcoidosis in U.S. Veterans from 2003 to 2019. Annals of the American Thoracic Society 2023. PMID: 36724377


  11. Verma A, Minnier J, Wan ES, Huffman JE, Gao L, Joseph J, Ho YL, Wu WC, Cho K, Gorman BR, Rajeevan N, Pyarajan S, Garcon H, Meigs JB, Sun YV, Reaven PD, McGeary JE, Suzuki A, Gelernter J, Lynch JA, Peterson JM, Zekavat SM, Natarajan P, Dalal S, Jhala DN, Arjomandi M, Gatsby E, Lynch KE, Bonomo RA, Freiberg M, Pathak GA, Zhou JJ, Donskey CJ, Madduri RK, Wells QS, Huang RD, Polimanti R, Chang KM, Liao KP, Tsao PS, Wilson PWF, Hung A, O'Donnell CJ, Gaziano JM, Hauger RL, Iyengar SK, Luoh SW, Million Veteran Program COVID-19 Science Initiative. A MUC5B Gene Polymorphism, rs35705950-T Confers Protective Effects Against COVID-19 Hospitalization but not Severe Disease or Mortality. American journal of respiratory and critical care medicine 2022. PMID: 35771531


  12. Fortis S, Quibrera PM, Comellas AP, Bhat SP, Tashkin DP, Hoffman EA, Criner GJ, Han MK, Barr RG, Arjomandi M, Dransfield MB, Peters SP, Dolezal BA, Kim V, Putcha N, Rennard SI, Paine R, Kanner RE, Curtis JL, Bowler RP, Martinez FJ, Hansel NN, Krishnan JA, Woodruff PG, Barjaktarevic IZ, Couper D, Anderson WH, Cooper CB, Subpopulations and Intermediate Outcome Measures in COPD Study Investigators. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD. Chest 2022. PMID: 36395858


  13. Falvo MJ, Sotolongo AM, Osterholzer JJ, Robertson MW, Kazerooni EA, Amorosa JK, Garshick E, Jones KD, Galvin JR, Kreiss K, Hines SE, Franks TJ, Miller RF, Rose CS, Arjomandi M, Krefft SD, Morris MJ, Polosukhin VV, Blanc PD, D'Armiento JM. Consensus statements on deployment-related respiratory disease, inclusive of constrictive bronchiolitis: A modified Delphi study. Chest 2022. PMID: 36343686


  14. Han MK, Ye W, Wang D, White E, Arjomandi M, Barjaktarevic IZ, Brown SA, Buhr RG, Comellas AP, Cooper CB, Criner GJ, Dransfield MT, Drescher F, Folz RJ, Hansel NN, Kaner RJ, Kanner RE, Krishnan JA, Lazarus SC, Maddipati V, Martinez FJ, Mathews A, Meldrum C, McEvoy C, Nyunoya T, Rogers L, Stringer WW, Wendt CH, Wise RA, Wisniewski SR, Sciurba FC, Woodruff PG, RETHINC Study Group. Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. The New England journal of medicine 2022. PMID: 36066078


  15. Buhr RG, Barjaktarevic IZ, Quibrera PM, Bateman LA, Bleecker ER, Couper DJ, Curtis JL, Dolezal BA, Han MK, Hansel NN, Krishnan JA, Martinez FJ, McKleroy W, Paine Iii R, Rennard SI, Tashkin DP, Woodruff PG, Kanner RE, Cooper CB, SPIROMICS investigators. Reversible Airflow Obstruction Predicts Future COPD Development in the SPIROMICS Cohort. 2022. PMID: 35549640


  16. Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, Barr RG, Comellas AP, Couper D, Cooper CB, Freeman C, Han M, Kaner RJ, Labaki W, Martinez FJ, Ortega VE, Peters SP, Paine R, Woodruff P, Curtis JL, Huffnagle GB, Stringer KA, Bowler RP, Esther CR, Reisdorph N, Huang YJ, SPIROMICS Research Group. Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage COPD. 2022. PMID: 35536732


  17. Davis CW, Rabin AS, Jani N, Osterholzer JJ, Krefft S, Hines SE, Arjomandi M, Robertson MW, Sotolongo AM, Falvo MJ, Post-Deployment Cardiopulmonary Evaluation Network. Postdeployment Respiratory Health: The Roles of the Airborne Hazards and Open Burn Pit Registry and the Post-Deployment Cardiopulmonary Evaluation Network. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2022. PMID: 36425809


  18. Simoneau CR, Chen PY, Xing GK, Khalid MM, Meyers NL, Hayashi JM, Taha TY, Leon KE, Ashuach T, Fontaine KA, Rodriguez L, Joehnk B, Walcott K, Vasudevan S, Fang X, Maishan M, Schultz S, Roose J, Matthay MA, Sil A, Arjomandi M, Yosef N, Ott M. NF-?B inhibitor alpha has a cross-variant role during SARS-CoV-2 infection in ACE2-overexpressing human airway organoids. bioRxiv : the preprint server for biology 2022. PMID: 35982664


  19. Verma A, Huffman JE, Gao L, Minnier J, Wu WC, Cho K, Ho YL, Gorman BR, Pyarajan S, Rajeevan N, Garcon H, Joseph J, McGeary JE, Suzuki A, Reaven PD, Wan ES, Lynch JA, Petersen JM, Meigs JB, Freiberg MS, Gatsby E, Lynch KE, Zekavat SM, Natarajan P, Dalal S, Jhala DN, Arjomandi M, Bonomo RA, Thompson TK, Pathak GA, Zhou JJ, Donskey CJ, Madduri RK, Wells QS, Gelernter J, Huang RDL, Polimanti R, Chang KM, Liao KP, Tsao PS, Sun YV, Wilson PWF, O'Donnell CJ, Hung AM, Gaziano JM, Hauger RL, Iyengar SK, Luoh SW, VA Million Veteran Program COVID-19 Science Initiative. Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait. JAMA internal medicine 2022. PMID: 35759254


  20. Mustra Rakic J, Zeng S, Rohdin-Bibby L, Van Blarigan EL, Liu X, Ma S, Kane JP, Redberg RF, Turino GM, Oestreicher Stock E, Arjomandi M. Elastin Degradation and Lung Function Deterioration with Remote Secondhand Tobacco Smoke Exposure in Never-smokers. 2022. PMID: 35700534


  21. Arjomandi M, Wong H, Tenney R, Holland N, Balmes JR. Effect of ozone on allergic airway inflammation. The journal of allergy and clinical immunology. Global 2022. PMID: 36643820


  22. Ronish BE, Couper DJ, Barjaktarevic IZ, Cooper CB, Kanner RE, Pirozzi CS, Kim V, Wells JM, Han MK, Woodruff PG, Ortega VE, Peters SP, Hoffman EA, Buhr RG, Dolezal BA, Tashkin DP, Liou TG, Bateman LA, Schroeder JD, Martinez FJ, Barr RG, Hansel NN, Comellas AP, Rennard SI, Arjomandi M, Paine Iii R. Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. 2022. PMID: 35114743


  23. Peloso GM, Tcheandjieu C, McGeary JE, Posner DC, Ho YL, Zhou JJ, Hilliard AT, Joseph J, O'Donnell CJ, Efird JT, Crawford DC, Wu WC, Arjomandi M, VA Million Veteran Program COVID-19 Science Initiative, Sun YV, Assimes TL, Huffman JE. Genetic Loci Associated With COVID-19 Positivity and Hospitalization in White, Black, and Hispanic Veterans of the VA Million Veteran Program. 2022. PMID: 35222515


  24. Frampton MW, Balmes JR, Bromberg PA, Arjomandi M, Hazucha MJ, Thurston SW, Alexis NE, Ganz P, Zareba W, Koutrakis P, Thevenet-Morrison K, Rich DQ. Effects of short-term increases in personal and ambient pollutant concentrations on pulmonary and cardiovascular function: A panel study analysis of the Multicenter Ozone Study in oldEr subjects (MOSES 2). 2021. PMID: 34919956


  25. Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R, Woodruff PG, Han MK, Martinez FJ, Barr RG, Wells JM, Ortega VE, Hoffman EA, Kim V, Drummond MB, Bowler RP, Curtis JL, Cooper CB, Tashkin DP, Barjaktarevic IZ. Significance of FEV3/FEV6 in recognition of early airway disease in smokers at risk of development of COPD: Analysis of the SPIROMICS cohort. 2021. PMID: 34767825


  26. Chen J, Weldemichael L, Zeng S, Giang B, Geerts J, Ching WC, Nishihama M, Gold WM, Arjomandi M. Actigraphy informs distinct patient-centered outcomes in Pre-COPD. Respiratory medicine 2021. PMID: 34496341


  27. Liu Q, Tian X, Maruyama D, Arjomandi M, Prakash A. Lung immune tone via gut-lung axis: gut-derived LPS and short-chain fatty acids' immunometabolic regulation of lung IL-1β, FFAR2, and FFAR3 expression. American journal of physiology. Lung cellular and molecular physiology 2021. PMID: 33851870


  28. Fortis S, Comellas A, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M, Hoesterey D, Buhr RG, Barr RG, Dolezal B, Ortega VE, Drummond MB, Arjomandi M, Kaner RJ, Kim V, Curtis JL, Bowler RP, Martinez F, Labaki WW, Cooper CB, O'Neal WK, Criner G, Hansel NN, Krishnan JA, Woodruff P, Couper D, Tashkin D, Barjaktarevic I. Ratio of Forced Expiratory Volume in 1 second /Slow Vital Capacity (FEV1/SVC)<0.7 is associated with clinical, functional, and radiologic features of obstructive lung disease in smokers with preserved lung function. Chest 2021. PMID: 33539837


  29. Vasudevan S, Vásquez JJ, Chen W, Aguilar-Rodriguez B, Niemi EC, Zeng S, Tamaki W, Nakamura MC, Arjomandi M. Lower PDL1/2 and AXL Expression on Lung Myeloid Cells Suggests Inflammatory Bias in Smoking and COPD. American journal of respiratory cell and molecular biology 2020. PMID: 32915645


  30. Rich DQ, Thurston SW, Balmes JR, Bromberg PA, Arjomandi M, Hazucha MJ, Alexis NE, Ganz P, Zareba W, Thevenet-Morrison K, Koutrakis P, Frampton MW. Does Ambient Ozone or Other Pollutants Modify Effects of Controlled Ozone Exposure on Pulmonary Function? Annals of the American Thoracic Society 2020. PMID: 32125874


  31. Sotolongo A, Falvo M, Santos S, Johnson I, Arjomandi M, Hines S, Krefft S, Osterholzer J. Military Burn Pits. American journal of respiratory and critical care medicine 2020. PMID: 32233853


  32. Rich DQ, Frampton MW, Balmes JR, Bromberg PA, Arjomandi M, Hazucha MJ, Thurston SW, Alexis NE, Ganz P, Zareba W, Koutrakis P, Thevenet-Morrison K. Multicenter Ozone Study in oldEr Subjects (MOSES): Part 2. Effects of Personal and Ambient Concentrations of Ozone and Other Pollutants on Cardiovascular and Pulmonary Function. Research report (Health Effects Institute) 2020. PMID: 32239870


  33. Blagev DP, Collingridge DS, Rea S, Carey KA, Mularski RA, Zeng S, Arjomandi M, Press VG. Laboratory-based Intermountain Validated Exacerbation (LIVE) Score stability in patients with chronic obstructive pulmonary disease. BMJ open respiratory research 2020. PMID: 32060034


  34. Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Paine Iii R, Bhatt SP, Bhakta NR, Arjomandi M, Kaner RJ, Pirozzi CS, Curtis JL, O'Neal WK, Woodruff PG, Han MK, Martinez FJ, Hansel N, Wells JM, Ortega VE, Hoffman EA, Doerschuk CM, Kim V, Dransfield MT, Drummond MB, Bowler R, Criner G, Christenson SA, Ronish B, Peters SP, Krishnan JA, Tashkin DP, Cooper CB. Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis. International journal of chronic obstructive pulmonary disease 2019. PMID: 31908441


  35. Arjomandi M, Zeng S, Barjaktarevic I, Barr RG, Bleecker ER, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Cooper CB, Couper DJ, Curtis JL, Dransfield MT, Han MK, Hansel NN, Hoffman EA, Kaner RJ, Kanner RE, Krishnan JA, Paine R, Peters SP, Rennard SI, Woodruff PG. Radiographic Lung Volumes Predict Progression to COPD in Smokers with Preserved Spirometry in SPIROMICS. The European respiratory journal 2019. PMID: 31439683


  36. Balmes JR, Arjomandi M, Bromberg PA, Costantini MG, Dagincourt N, Hazucha MJ, Hollenbeck-Pringle D, Rich DQ, Stark P, Frampton MW. Ozone effects on blood biomarkers of systemic inflammation, oxidative stress, endothelial function, and thrombosis: The Multicenter Ozone Study in oldEr Subjects (MOSES). PloS one 2019. PMID: 31553765


  37. Zeng S, Tham A, Bos B, Jin J, Arjomandi M. Back to the Box: Using Lung Volumes to Predict Susceptibility to Develop Chronic Obstructive Pulmonary Disease among Smokers. Annals of the American Thoracic Society 2018. PMID: 30759017


  38. Vasudevan S, Vasquez J, Chen W, Zeng S, Arjomandi M. Inflammatory Phenotypes Associated with Chronic Obstructive Pulmonary Disease Increase Susceptibility to Exacerbation. Lessons from Single Cell Analysis of Lung Macrophages. Annals of the American Thoracic Society 2018. PMID: 30759013


  39. Trivedi NN, Brown JK, Rubenstein T, Rostykus AD, Fish AL, Yu H, Carbonell L, Juang A, Kamer S, Patel B, Sidhu M, Vuong D, Wang S, Beggs M, Wu AH, Arjomandi M. Analytical validation of a novel multi-analyte plasma test for lung nodule characterization. Biomedical research and reviews 2018. PMID: 32923944


  40. Trivedi NN, Arjomandi M, Brown JK, Rubenstein T, Rostykus AD, Esposito S, Axler E, Beggs M, Yu H, Carbonell L, Juang A, Kamer S, Patel B, Wang S, Fish AL, Haddad Z, Wu AH. Risk assessment for indeterminate pulmonary nodules using a novel, plasma-protein based biomarker assay. Biomedical research and clinical practice 2018. PMID: 32913898


  41. A. Fish, A. Vachani, M. Beggs, L. Carbonell, Z. Haddad, A. Juang, S. Kamer, B. Patel, H. Yu, A. Wu, P. Massion, M. Arjomandi, J. Brown, N. Trivedi, T. Rubenstein. MA23.03 Risk Assessment for Indeterminate Pulmonary Nodules Using a Novel, Plasma-Protein Based Biomarker Assay. Journal of Thoracic Oncology 2018. PMID:


  42. Lee SM, Tenney R, Wallace AW, Arjomandi M. E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. PeerJ 2018. PMID: 30280019


  43. Zeng S, Tham A, Bos B, Jin J, Giang B, Arjomandi M. Lung volume indices predict morbidity in smokers with preserved spirometry. Thorax 2018. PMID: 30030304


  44. Rich DQ, Balmes JR, Frampton MW, Zareba W, Stark P, Arjomandi M, Hazucha MJ, Costantini MG, Ganz P, Hollenbeck-Pringle D, Dagincourt N, Bromberg PA. Cardiovascular function and ozone exposure: The Multicenter Ozone Study in oldEr Subjects (MOSES). Environment international 2018. PMID: 29980042


  45. Ghasemiesfe M, Ravi D, Vali M, Korenstein D, Arjomandi M, Frank J, Austin PC, Keyhani S. Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis. Annals of internal medicine 2018. PMID: 29971337


  46. Blagev DP, Collingridge DS, Rea S, Press VG, Churpek MM, Carey K, Mularski RA, Zeng S, Arjomandi M. Stability of Frequency of Severe Chronic Obstructive Pulmonary Disease Exacerbations and Health Care Utilization in Clinical Populations. Chronic obstructive pulmonary diseases (Miami, Fla.) 2018. PMID: 30584584


  47. Blagev DP, Collingridge DS, Rea S, Horne BD, Press VG, Churpek MM, Carey KA, Mularski RA, Zeng S, Arjomandi M. The Laboratory-Based Intermountain Validated Exacerbation (LIVE) Score Identifies Chronic Obstructive Pulmonary Disease Patients at High Mortality Risk. Frontiers in medicine 2018. PMID: 29942803


  48. Arjomandi M, Balmes JR, Frampton MW, Bromberg P, Rich DQ, Stark P, Alexis NE, Costantini M, Hollenbeck-Pringle D, Dagincourt N, Hazucha MJ. Respiratory Responses to Ozone Exposure: The Multicenter Ozone Study in oldEr Subjects (MOSES). Volume 197 of Issue 10. American journal of respiratory and critical care medicine 2017. PMID: 29232153


  49. Arjomandi M, Zeng S, Geerts J, Stiner RK, Bos B, van Koeverden I, Keene J, Elicker B, Blanc PD, Gold WM. Lung volumes identify an at-risk group in persons with prolonged secondhand tobacco smoke exposure but without overt airflow obstruction. Volume 5 of Issue 1. BMJ open respiratory research 2018. PMID: 29755755


  50. Schneiderman AI, Dougherty DD, Fonseca VP, Wolters CL, Bossarte RM, Arjomandi M. Diagnosing Chronic Obstructive Pulmonary Disease Among Afghanistan and Iraq Veterans: Veterans Affair's Concordance With Clinical Guidelines for Spirometry Administration. Military medicine 2017. PMID: 28885968


  51. Frampton MW, Balmes JR, Bromberg PA, Stark P, Arjomandi M, Hazucha MJ, Rich DQ, Hollenbeck-Pringle D, Dagincourt N, Alexis N, Ganz P, Zareba W, Costantini MG. Multicenter Ozone Study in oldEr Subjects (MOSES): Part 1. Effects of Exposure to Low Concentrations of Ozone on Respiratory and Cardiovascular Outcomes. Research report (Health Effects Institute) 2017. PMID: 31898880


  52. Tham A, Lullo D, Dalton S, Zeng S, van Koeverden I, Arjomandi M. Modeling vascular inflammation and atherogenicity after inhalation of ambient levels of ozone: exploratory lessons from transcriptomics. Inhalation toxicology 2017. PMID: 28412860


  53. Miren Guenechea-Sola, Sarah Dalton, Jeroen Geerts, Siyang Zeng, Mehrdad Arjomandi. Asthma-COPD Overlap Syndrome- an Underdiagnosed Phenotype in Heavy Smokers. Journal of Allergy and Clinical Immunology 2016. PMID:


  54. Leroy P, Tham A, Wong H, Tenney R, Chen C, Stiner R, Balmes JR, Paquet AC, Arjomandi M. Inflammatory and repair pathways induced in human bronchoalveolar lavage cells with ozone inhalation. Volume 10 of Issue 6. PloS one 2015. PMID: 26035830


  55. Arjomandi M, Wong H, Donde A, Frelinger J, Dalton S, Ching W, Power K, Balmes JR. Exposure to medium and high ambient levels of ozone causes adverse systemic inflammatory and cardiac autonomic effects. Volume 308 of Issue 12. American journal of physiology. Heart and circulatory physiology 2015. PMID: 25862833


  56. Holland N, Davé V, Venkat S, Wong H, Donde A, Balmes JR, Arjomandi M. Ozone inhalation leads to a dose-dependent increase of cytogenetic damage in human lymphocytes. Volume 56 of Issue 4. Environmental and molecular mutagenesis 2014. PMID: 25451016


  57. Bhattacharya M, Sundaram A, Kudo M, Farmer J, Ganesan P, Khalifeh-Soltani A, Arjomandi M, Atabai K, Huang X, Sheppard D. IQGAP1-dependent scaffold suppresses RhoA and inhibits airway smooth muscle contraction. Volume 124 of Issue 11. The Journal of clinical investigation 2014. PMID: 25271629


  58. van Koeverden I, Blanc PD, Bowler RP, Arjomandi M. Secondhand Tobacco Smoke and COPD Risk in Smokers: A COPDGene Study Cohort Subgroup Analysis. Volume 12 of Issue 2. COPD 2014. PMID: 24983136


  59. . Hidden Costs of Climate Change: Contribution of Ozone to Human Diseases Proceedings of the American Association for the Advancement of Science. Proceedings of the U.S.-Iran Symposium on Air Pollution in Megacities. 2013. PMID:


  60. Kudo M, Khalifeh Soltani SM, Sakuma SA, McKleroy W, Lee TH, Woodruff PG, Lee JW, Huang K, Chen C, Arjomandi M, Huang X, Atabai K. Mfge8 suppresses airway hyperresponsiveness in asthma by regulating smooth muscle contraction. Volume 110 of Issue 2. Proceedings of the National Academy of Sciences of the United States of America 2012. PMID: 23269839


  61. Mehrdad Arjomandi, Subha Venkat, Hofer Wong, Aneesh Donde, John Balmes, Nina Holland. Oxidative Injury Due to Inhalation of Ozone Causes Dose-Dependent Cytogenetic Damage in Peripheral Blood Lymphocytes. Annals of the American Thoracic Society 2012. PMID:


  62. Arjomandi M, Haight T, Sadeghi N, Redberg R, Gold WM. Reduced exercise tolerance and pulmonary capillary recruitment with remote secondhand smoke exposure. Volume 7 of Issue 4. PloS one 2012. PMID: 22493689


  63. Donde A, Wong H, Frelinger J, Power K, Balmes JR, Arjomandi M. Effects of exercise on systemic inflammatory, coagulatory, and cardiac autonomic parameters in an inhalational exposure study. Volume 54 of Issue 4. Journal of occupational and environmental medicine 2012. PMID: 22418276


  64. Arjomandi M, Galanter JM, Choudhry S, Eng C, Hu D, Beckman K, Chapela R, Rodríguez-Santana JR, Rodríguez-Cintrón W, Ford J, Avila PC, Burchard EG. Polymorphism in Osteopontin Gene (SPP1) Is Associated with Asthma and Related Phenotypes in a Puerto Rican Population. Volume 24 of Issue 4. Pediatric allergy, immunology, and pulmonology 2011. PMID: 22276228


  65. Arjomandi M, Frelinger J, Donde A, Wong H, Yellamilli A, Raymond W. Secreted osteopontin is highly polymerized in human airways and fragmented in asthmatic airway secretions. PloS one 2011. PMID: 22031818


  66. Goolaerts A, Lafargue M, Song Y, Miyazawa B, Arjomandi M, Carlès M, Roux J, Howard M, Parks DA, Iles KE, Pittet JF. PAI-1 is an essential component of the pulmonary host response during Pseudomonas aeruginosa pneumonia in mice. Thorax 2011. PMID: 21768189


  67. Arjomandi M, Seward J, Gotway MB, Nishimura S, Fulton GP, Thundiyil J, King TE, Harber P, Balmes JR. Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. Volume 52 of Issue 6. Journal of occupational and environmental medicine 2010. PMID: 20523233


  68. Arjomandi M, Haight T, Redberg R, Gold WM. Pulmonary function abnormalities in never-smoking flight attendants exposed to secondhand tobacco smoke in the aircraft cabin. Volume 51 of Issue 6. Journal of occupational and environmental medicine 2009. PMID: 19448573


  69. Arjomandi M, Tager IB, Bastaki M, Chen C, Holland N, Balmes JR. Is there an association between lifetime cumulative exposure and acute pulmonary responses to ozone? Volume 50 of Issue 3. Journal of occupational and environmental medicine 2008. PMID: 18332784


  70. Chen C, Arjomandi M, Balmes J, Tager I, Holland N. Effects of chronic and acute ozone exposure on lipid peroxidation and antioxidant capacity in healthy young adults. Volume 115 of Issue 12. Environmental health perspectives 2007. PMID: 18087591


  71. Chen C, Arjomandi M, Tager IB, Holland N, Balmes JR. Effects of antioxidant enzyme polymorphisms on ozone-induced lung function changes. The European respiratory journal 2007. PMID: 17652311


  72. Chen C, Arjomandi M, Qin H, Balmes J, Tager I, Holland N. Cytogenetic damage in buccal epithelia and peripheral lymphocytes of young healthy individuals exposed to ozone. Volume 21 of Issue 2. Mutagenesis 2006. PMID: 16513656


  73. Witten A, Solomon C, Abbritti E, Arjomandi M, Zhai W, Kleinman M, Balmes J. Effects of nitrogen dioxide on allergic airway responses in subjects with asthma. Volume 47 of Issue 12. Journal of occupational and environmental medicine 2005. PMID: 16340706


  74. Arjomandi M, Schmidlin I, Girling P, Boylen K, Ferrando R, Balmes J. Sputum induction and bronchoscopy for assessment of ozone-induced airway inflammation in asthma. Volume 128 of Issue 1. Chest 2005. PMID: 16002965


  75. Arjomandi M, Witten A, Abbritti E, Reintjes K, Schmidlin I, Zhai W, Solomon C, Balmes J. Repeated exposure to ozone increases alveolar macrophage recruitment into asthmatic airways. Volume 172 of Issue 4. American journal of respiratory and critical care medicine 2005. PMID: 15937293


  76. Wang BY, Candipan RC, Arjomandi M, Hsiun PT, Tsao PS, Cooke JP. Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. Journal of the American College of Cardiology 1996. PMID: 8917274


  77. Renoir JM, Le Bihan S, Mercier-Bodard C, Gold A, Arjomandi M, Radanyi C, Baulieu EE. Effects of immunosuppressants FK506 and rapamycin on the heterooligomeric form of the progesterone receptor. The Journal of steroid biochemistry and molecular biology 1994. PMID: 7510997